Clinical Trial Update: - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of fruquintinib with tislelizumab in patients with MSS/pMMR metastatic colorectal cancer without active liver metastase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Elunate (fruquintinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: RECRUITING